Tmunity Therapeutics

Tmunity Therapeutics is a biotechnology company developing t-cell immunotherapies for the treatment of human diseases that is headquartered in Philadelphia, Pennsylvania. It was founded in 2015 by Carl June, Bruce Levine, Yangbing Zhao, Anne Chew, James Riley, and Bruce Blazar.

Product

The company conducts research and development around the aforementioned field of study. It uses laboratory and production facilities at the University of Pennsylvania, as well as its own production facility located near the city. It has multiple novel therapies, many of which are in the pre-clinical and clinical stages of development.

Timeline

October 31, 2029

Tmunity Therapeutics raises a $75,000,000 series B round.

November 2019

Tmunity Therapeutics raises a $75,000,000 series B round from Andreessen Horowitz, Be The Match BioTherapies, Gilead Sciences and Westlake Village BioPartners.

October 2019

Tmunity Therapeutics raises a $74,999,948 series B round from American Cancer Society, Andreessen Horowitz, Be The Match, Be The Match BioTherapies, Gilead Sciences, The a16z Cultural Leadership Fund, University of Pennsylvania and Westlake Village BioPartners.

January 23, 2018

Tmunity Therapeutics raises a $100,000,000 series A round.

January 23, 2018

Tmunity Therapeutics raises a $100,000,000 series A round from Be The Match BioTherapies, Gilead Sciences and Lilly Asia Ventures.

2015

Tmunity Therapeutics was founded by Dr. Anne Chew, Dr. Bruce Levine, Dr. Carl H. June, Dr. James L. Riley and Dr. Yangbing Zhao.

Funding rounds

Patents

Further Resources

Title

Author

Link

Type

Date

Tmunity Therapeutics

https://www.youtube.com/watch?v=oxyak9icO-Y

April 27, 2018

Tmunity Therapeutics Raises $100 Million in Series A Financing to Advance Portfolio of Next-Generation T cell Immunotherapies to Transform the Treatment of Cancer

Business Wire

https://www.businesswire.com/news/home/20180123005486/en/Tmunity-Therapeutics-Raises-100-Million-Series-Financing

Web

Tmunity Therapeutics, Inc. to Advance IND-Enabling Activities for Personalized Next-Generation Engineered T Cell Therapies with $10 Million Financing

Tmunity Therapeutics

https://www.prnewswire.com/news-releases/tmunity-therapeutics-inc-to-advance-ind-enabling-activities-for-personalized-next-generation-engineered-t-cell-therapies-with-10-million-financing-300203157.html

Web

News

Title

Author

Date

Publisher

Description

Tmunity stops solid tumor CAR-T trial after 2 patients die

Nick Paul

June 3, 2021

FierceBiotech

Tmunity Therapeutics has stopped development of its lead CAR-T therapy after two patients died of a form of neurotoxicity. The news, details of which were first reported by Endpoints, has implications for the broader push to establish cell therapies as treatments for solid tumors.

Tmunity expands Penn pact, picking up another CAR-T program, rights to manufacturing tech

Amirah Al Idrus

February 9, 2021

FierceBiotech

Tmunity Therapeutics was born out of an extensive collaboration with the University of Pennsylvania that netted it the technology, know-how and programs it needed to go after better cell therapies for cancer. Now, the biotech is bolstering that pact, picking up a new CAR-T program and the rights to certain technologies.

Timeline

Funding rounds

Patents

Further Resources

News

References

Company attributes

Other attributes

Categories

Related Topics

Contributors